PP
SWTX

PDT Partners’s SpringWorks Therapeutics SWTX Stock Holding History

PDT Partners’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,387
Closed -$1.31M – 713
2022
Q4 		$1.31M Sell
50,387
-21,160
-30% -$521K 0.21% 166
2022
Q3 		$2.04M Sell
71,547
-17,235
-19% -$494K 0.31% 65
2022
Q2 		$2.19M Buy
+88,782
New +$3.25M 0.19% 153
2022
Q1 		– Sell
-33,500
Closed -$2.08M – 1106
2021
Q4 		$2.08M Buy
33,500
+24,896
+289% +$1.65M 0.16% 226
2021
Q3 		$546K Buy
+8,604
New +$663K 0.04% 458

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

PDT Partners's SWTX Position: Q1 2023 in Review

PDT Partners sold out of SpringWorks Therapeutics (SWTX) in Q1 2023, closing a stake of 50,387 shares — an estimated $1.31M sold.

PDT Partners first reported a position in SWTX in Q3 2021 and held it in 5 quarters. The position peaked at $2.19M in Q2 2022. 148 funds tracked by Wall St. Rank hold SWTX as of Q1 2023.

  • PDT Partners reported no remaining SpringWorks Therapeutics position as of Q1 2023 after selling out during the quarter.
  • PDT Partners sold 50,387 SpringWorks Therapeutics shares in Q1 2023, an estimated $1.31M.
  • PDT Partners first reported a position in SpringWorks Therapeutics in Q3 2021 and held it in 5 quarters.
  • PDT Partners's SpringWorks Therapeutics position peaked at $2.19M in Q2 2022.
  • 148 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2023.

Based on PDT Partners's 13F filing for Q1 2023, filed 15 May 2023.